|By PR Newswire||
|December 24, 2013 08:00 AM EST||
NEW YORK, December 24, 2013 /PRNewswire/ --
Today, Analysts' Corner announced new research reports highlighting Horizon Pharma, Inc. (NASDAQ: HZNP), Novavax, Inc. (NASDAQ: NVAX), WuXi PharmaTech (Cayman) Inc. (NYSE: WX), Chelsea Therapeutics International Ltd. (NASDAQ: CHTP), and Anika Therapeutics Inc. (NASDAQ: ANIK). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Horizon Pharma, Inc. Research Report
On December 19, 2013, Horizon Pharma, Inc. (Horizon Pharma) announced that on December 18, 2013, the Compensation Committee of the Company's Board of Directors has approved the grant of inducement stock options to purchase an aggregate of 88,000 shares of common stock to 22 new employees. According to the Company, each stock option has an exercise price of $6.78 per share. Horizon Pharma further stated that each stock option has a ten year term and is subject to the terms and conditions of the Company's 2011 Equity Incentive Plan and the stock option agreement pursuant to which the option was granted. The Full Research Report on Horizon Pharma, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Novavax, Inc. Research Report
On December 19, 2013, Novavax, Inc.'s (Novavax) stock reflected an increase of 3.77%, and closed the day at $4.68 per share. Over the period of past three trading days, the Company's stock increased by 1.52%, compared to the Dow Jones Industrial Average which went up by 1.85%, and the Nasdaq composite which went up by 0.71%, over the same three day trading period. The Full Research Report on Novavax, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
WuXi PharmaTech (Cayman) Inc. Research Report
On December 19, 2013, WuXi PharmaTech (Cayman) Inc.'s (WuXi PharmaTech) stock was up by 3.55%, closing the day at $35.61 per share. Over the past three-day trading period, the Company's stock went up by 8.37%, compared to S&P 500 which went up by 1.29% during the same three-day trading period. The Full Research Report on WuXi PharmaTech (Cayman) Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Chelsea Therapeutics International Ltd. Research Report
On December 9, 2013, Chelsea Therapeutics International Ltd. (Chelsea Therapeutics) announced that the first patient has been dosed in Study 401, a multi-center, multi-national, randomized, parallel-group, placebo-controlled, double-blind study of investigational drug NORTHERA™ (droxidopa). The Company reported that NORTHERA is an orally active synthetic precursor of norepinephrine, being studied for the treatment of symptomatic neurogenic orthostatic hypotension (nOH) in patients with primary autonomic failure (such as Parkinson's disease, multiple system atrophy and pure autonomic failure), dopamine beta hydroxylase deficiency and non-diabetic autonomic neuropathy. According to Chelsea Therapeutics, the Company expects Study 401 to enroll approximately 450 patients. Additionally, Joseph G. Oliveto, Interim CEO of the Company, stated, "Chelsea is committed to understanding the long-term safety and durability of Northera in symptomatic nOH, a goal we hope to achieve through Study 401, the largest randomized, placebo-controlled study undertaken in this orphan indication." Oliveto added, "We thank the many investigators who have committed to participating in this global study, as well as the patients and their families who will take part in it. There exists a significant unmet need in nOH, and it remains Chelsea's goal to bring new treatment options to those suffering from this debilitating condition." The Full Research Report on Chelsea Therapeutics International Ltd. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Anika Therapeutics Inc. Research Report
On December 19, 2013, Anika Therapeutics Inc.'s (Anika Therapeutics) stock went up by 3.45% at $35.69 per share. The Company's stock went up by 5.16% over the past three-day trading period, compared to the Dow Jones Industrial Average which went up by 1.85%, and the Nasdaq composite which went up by 0.71%, during the same trading period. The Full Research Report on Anika Therapeutics Inc.- including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
- For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts' Corner